Vulvodynia Treatment Market
Market Insights on Vulvodynia Treatment covering sales outlook, demand forecast & up-to-date key trends
Vulvodynia Treatment Market by Drug Class (Local Anesthetics, Anticonvulsant, Tricyclic Antidepressants, Hormones, Serotonin-norepinephrine Reuptake Inhibitors (SNRIs), Nerve Blocks), Mode of Application (Oral, Topical, Injection) & Region for 2022-2028
Vulvodynia Treatment Market Outlook (2022-2028)
[246 Pages Report] Revenue from the global Vulvodynia Treatment Market is currently valued at US$ 5.6 Bn, and is projected to top US$ 8 Bn by 2028, increasing at an impressive CAGR of 6.3% over the period of 2022 to 2028.
|
Global Vulvodynia Treatment Market Size (2022) |
US$ 5.6 Bn |
|
Revenue Forecast (2028) |
US$ 8 Bn |
|
Global Market Growth Rate (2022-2028) |
6.3% CAGR |
|
North America Market Share |
30.2% |
Vulvodynia treatment currently accounts for 73.4% share of the global neuropathic pain market, with North America and Western Europe leading the way as far as demand is concerned.
Let us know your requirement to get
100% FREE customization
How The Market Progressed Till June 2022?
|
Particulars |
Details |
|
H1, 2021 |
6.10% |
|
H1, 2022 Projected |
6.28% |
|
H1, 2022 Outlook |
6.18% |
|
BPS Change - H1, 2022 (O) – H1, 2022 (P) |
(-) 10 ↓ |
|
BPS Change – H1, 2022 (O) – H1, 2021 |
(+) 08 ↑ |
The comparative analysis and market growth rate of global vulvodynia treatment market as studied by Future Market Insights, will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 10 BPS, However, a positive BPS growth is expected in H1-2022 over H1- 2021 duration with 08 Basis Point Share (BPS).
The surge in the BPS values is associated with the advances in pain neuroscience and the central sensitization paradigm for the management of vulvodynia through a neurobiological stand-point.
Conversely, the decline in the BPS values observed was attributed to the reduced adoption of topical treatment options for vulvodynia, owed to its many side effects, thus reducing patient preference towards treatment regime. Moreover, less reported follow-ups after treatment have further resulted in the decline in the BPS values for the market.
The key developments in the market include the incorporation of physical therapy (massage therapy), combined with conversation therapy, and sexological treatment for vulvodynia and other chronic female disorders. Moreover, biofeedback therapy, local anaesthetics, nerve block injections, pelvic floor therapy and surgery have proven to be effective in the management of vulvodynia.
The market is highly influenced by regulatory dynamics, and licensing for drug distribution, under the impact of macro and industry factors. The market is subject to comprehensive medical research owed to government associated funding, and campaigns to promote disease indication for vulvodynia.
Vulvodynia Treatment Demand Analysis (2013 to 2021) Vs Market Outlook (2022 to 2028)
Vulvodynia is an unexplained, complex cause of chronic vulvar pain or discomfort that can affect women of all ages and in any reproductive phase. The disease's complicated genesis as well as the symptoms of concomitant pain syndrome make illness management challenging.
Vulvodynia pain has a bad impact on sexual health as well reproductive health. Although the symptoms of vulvodynia aren't life-threatening, they can nonetheless have a significant influence on one’s life. Physiology, emotions, experiences, beliefs, lifestyles, and relationships all have a role in sexual response. Any component that is disrupted can have an impact on sexual and reproductive health.
Vulvodynia treatment demand rose at a CAGR of 5.2% from 2013 to 2021. Several therapies have come about in recent years that aim to address the biological, psychological, and interpersonal variables that contribute to this illness. This is a critical aspect driving consistent growth of the global vulvodynia therapy market.
Better diagnostic techniques and disease models have increased our understanding of the disease phenotype, propelling the vulvodynia therapeutic industry forward. Vulvodynia treatment demand is predicted to increase at a high CAGR of 6.3% from 2022 to 2028, with the global market expected to cross a valuation of US$ 8 Bn by 2028.
Vulvodynia treatment at home has been performed since ages, where antidepressants and anticonvulsants have raised to the top of the list of vulvodynia therapy options. Vulvodynia treatment at home can help reduce pain to some extent. Individuals may need to attempt a variety of vulvodynia treatment at home before determining which ones are the most effective. It is also notable that vulvodynia treatment over the counter can be risky and one should consult doctor beforehand.
Which Factors are Expected to Drive Vulvodynia Treatment Market Growth?
“Anaesthetic Gels & Creams and Appropriate Diet Options Driving Market Growth”
Growing economic and social impact of vulvodynia is driving demand for vulvodynia therapies in different regions of the world. Rising awareness of the impact of vulvodynia on the healthcare systems in developed nations is also propelling the industry forward.
Growing knowledge of vulvodynia diagnostics among clinicians, particularly gynaecologists, is propelling the worldwide vulvodynia therapy market ahead. Advances in various therapeutic methods for vulvodynia management are projected to open up new opportunities for market players.
The industry's focus on multidisciplinary approaches to disease management has a positive impact on market prospects. A key trend driving vulvodynia demand growth is the increased acceptability of local anaesthetics in the form of gels or creams to reduce pain-related discomfort in the patient populations.
A good example is the increased demand for lidocaine gel or cream. Increased research on expanding first-line vulvodynia treatment is also fuelling the market's steady growth. It is also important not to repeatedly make use of over-the-counter vulvodynia treatment options without consulting a doctor.
The market will benefit from relentless research and development initiatives targeted at discovering a reliable therapeutic strategy for controlling vulvodynia. Unmet needs in vulvodynia therapy are likely to be addressed by the expanding number of psychophysical research programs.
A recent study shows that vulvodynia treatment diet plays an important role, and keeping patients on a particular diet can help recover from vulvodynia pain. Dieticians are now researching on particular vulvodynia treatment diets to lessen the discomfort.
Female sexual dysfunction has become a common problem worldwide, and can strike at any age. Female sexual dysfunction treatment performed under the guidance of a specialist can help overcome pain. Education and information on sexual health is also helping in raising awareness of female sexual dysfunction treatment across regions.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich Regional Markets are Set to Be Lucrative for Vulvodynia Treatment Providers?
“North America Handsomely Leading Global Vulvodynia Treatment Market”
These vulvodynia treatment market insights shed light on regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).
The North America vulvodynia treatment market is expected to account for the highest market share of around 30.2% in the global landscape in 2022. A recent Harvard study showed that there are approximately 6 Mn American women who are suffering from vulvodynia.
The vulvodynia treatment devices market in Western Europe and Eastern Europe are expected to be driven by rising popularity of vulvodynia treatment procedures, increasing medical research & development, etc. The Western Europe and Eastern Europe market together are set to account for 30.6% of the global market share in 2022.
The Latin America vulvodynia treatment market is set account for 10.1% of the global market share in 2022. APEJ is expected to be the third-most lucrative market with 19.6% market share in 2022. This is because of rapidly increasing penetration of generics in China and India.
The vulvodynia treatment equipment market in the MEA region is expected to progress at a slightly slower rate than other regions, but this trend is anticipated to change by the end of the forecast period. In 2022, the market in MEA is set to account for 3.2% of the global market share.
Country-wise Analysis
How is Demand for Vulvodynia Treatment Expected to Shape Up in the U.S.?
“Well-established Healthcare Infra in the U.S. Driving Vulvodynia Treatment”
The United States is one of the top countries driving vulvodynia treatment demand. The country's prospects are being boosted by the presence of well-developed healthcare infrastructure and the availability of skilled medical staff.
Throughout the projected period, the United States market is expected to grow at a robust rate. The country is boosting its spending on biopharmaceutical research and development in order to develop cures for uncommon diseases, which bodes well for vulvodynia treatment system providers in the country.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-wise Analysis
Which Vulvodynia Treatment Drug is Set to Gain Immense Popularity?
“Anticonvulsants Most Prescribed Vulvodynia Treatment Drugs”
Anticonvulsants are medications that are used to prevent seizures or stop a series of seizures from occurring (convulsions). Anticonvulsants are the most commonly prescribed medications for vulvodynia treatment.
Gabapentin is the most effective anticonvulsant medicine for the treatment of vulvodynia. Gabapentin is a medicine that has long been known as an excellent pain reliever in chronic pain management. It consists of tablets that are taken orally and are effective for nerve pain relief. These tablets are used to treat a variety of disorders that affect the central nervous system, as well as discomfort in the spinal cord. Another anticonvulsant is pregabalin. It's quite similar to gabapentin, but it's said to have fewer side effects and believed to be more effective.
Tricyclic antidepressants (TCAs) are a type of drug that are primarily used to treat depression. A doctor can prescribe them in lesser amounts than those used to treat depression. These medications are given because they change the way nerve fibres convey pain signals.
COVID-19 Impact on Market
Over the period of 2020 and 2021, the COVID-19 pandemic had a deleterious impact on most medical procedures. People were unable to visit hospitals for various medical treatments and procedures due to COVID-19 pandemic restrictions. The vulvodynia treatment market also saw a decrease in demand, as focus of the healthcare sector was mainly on COVID.
Also, due to supply chain disruptions, there was a shortage of the equipment, drugs, and materials needed to undertake successful vulvodynia treatment procedures. However, the global vulvodynia treatment market is recovering as respective government agencies have lifted most enforced lockdowns and restrictions.
Competitive Landscape
Companies are looking for therapies and medications that might alleviate the discomfort associated with vulvodynia in order to meet the demand of an increasing number of patients. They are spending more on research and development as well as mergers and acquisitions to achieve this. As a result, this will help them increase their target bases by being able to cater to both, global and domestic audiences.
Eli Lilly and Company, AstraZeneca Plc., GlaxoSmithKline Plc., Pfizer Inc., Johnson & Johnson Services, Inc., and Allergan plc are among the major vulvodynia treatment equipment manufacturers.
Vulvodynia Treatment Industry Report Scope
|
Attribute |
Details |
|
Forecast Period |
2022-2028 |
|
Historical Data Available for |
2013-2021 |
|
Market Analysis |
US$ Mn for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Segments of Vulvodynia Treatment Industry Survey
Vulvodynia Treatment Market by Drug Class:
- Local Anesthetics
- Anticonvulsant
- Tricyclic Antidepressants
- Hormones
- Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
- Nerve Blocks
- Others
Vulvodynia Treatment Market by Mode of Application:
- Oral Vulvodynia Treatment
- Topical Vulvodynia Treatment
- Injection Vulvodynia Treatment
Vulvodynia Treatment Market by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Store
- Online Pharmacies
Vulvodynia Treatment Market by Region:
- North America Vulvodynia Treatment Market
- Latin America Vulvodynia Treatment Market
- Europe Vulvodynia Treatment Market
- East Asia Vulvodynia Treatment Market
- South Asia & Pacific Vulvodynia Treatment Market
- Middle East & Africa (MEA) Vulvodynia Treatment Market
Frequently Asked Questions
The global vulvodynia treatment market is estimated to surge at a CAGR of 6.3% through 2028.
The global market for vulvodynia treatment is currently worth US$ 5.6 Bn.
Key vulvodynia treatment product providers are Eli Lilly and Company, AstraZeneca Plc., GlaxoSmithKline Plc., Pfizer Inc., Johnson & Johnson Services, Inc., and Allergan.
The global vulvodynia treatment market is anticipated to cross a valuation of US$ 8 Bn by 2028.
The Japan vulvodynia treatment market currently holds 6.3% share in the global market.
Table of Content
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Vulvodynia Treatment Market View Point
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Occurrence of Vulvodynia
3.4. Regulatory Scenario
4. Vulvodynia Treatment Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
4.4. Trends
5. North America Vulvodynia Treatment Market Analysis 2013–2021 and Forecast 2022–2028
5.1. Introduction
5.2. Regional Market Dynamics
5.3. Historical Market Size (US$ Mn) By Country, 2013-2021
5.3.1. U.S.
5.3.2. Canada
5.4. Market Size (US$ Mn) Forecast By Country, 2022-2028
5.4.1. U.S.
5.4.2. Canada
5.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2021
5.5.1. Anticonvulsant
5.5.2. Tricyclic Antidepressant
5.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
5.5.4. Hormone
5.5.5. Nerve Block
5.5.6. Local Anesthetic
5.5.7. Others
5.6. Market Size (US$ Mn) Forecast and By Drug Class, 2022–2028
5.6.1. Anticonvulsant
5.6.2. Tricyclic Antidepressant
5.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
5.6.4. Hormone
5.6.5. Nerve Block
5.6.6. Local Anesthetic
5.6.7. Others
5.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2021
5.7.1. Oral
5.7.2. Topical
5.7.3. Injectable
5.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2022–2028
5.8.1. Oral
5.8.2. Topical
5.8.3. Injectable
5.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2021
5.9.1. Hospital Pharmacies
5.9.2. Retail Pharmacies
5.9.3. Drug Stores
5.9.4. Online Pharmacies
5.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2022–2028
5.10.1. Hospital Pharmacies
5.10.2. Retail Pharmacies
5.10.3. Drug Stores
5.10.4. Online Pharmacies
5.11. Drivers and Restraints: Impact Analysis
5.12. Market Attractiveness Analysis
5.12.1. By Country
5.12.2. By Drug Class
5.12.3. By Mode Of Administration
5.12.4. By Distribution Channel
5.13. Key Representative Market Participants
5.14. Key Participants Market Presence (Intensity Map)
6. Latin America Vulvodynia Treatment Market Analysis 2013–2021 and Forecast 2022–2028
6.1. Introduction
6.2. Regional Market Dynamics
6.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013–2021
6.3.1. Brazil
6.3.2. Mexico
6.3.3. Rest of Latin America
6.4. Market Size (US$ Mn) Forecast By Country, 2022–2028
6.4.1. Brazil
6.4.2. Mexico
6.4.3. Rest of Latin America
6.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2021
6.5.1. Anticonvulsant
6.5.2. Tricyclic Antidepressant
6.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
6.5.4. Hormone
6.5.5. Nerve Block
6.5.6. Local Anesthetic
6.5.7. Others
6.6. Market Size (US$ Mn) Forecast and By Drug Class, 2022–2028
6.6.1. Anticonvulsant
6.6.2. Tricyclic Antidepressant
6.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
6.6.4. Hormone
6.6.5. Nerve Block
6.6.6. Local Anesthetic
6.6.7. Others
6.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2021
6.7.1. Oral
6.7.2. Topical
6.7.3. Injectable
6.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2022–2028
6.8.1. Oral
6.8.2. Topical
6.8.3. Injectable
6.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2021
6.9.1. Hospital Pharmacies
6.9.2. Retail Pharmacies
6.9.3. Drug Stores
6.9.4. Online Pharmacies
6.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2022–2028
6.10.1. Hospital Pharmacies
6.10.2. Retail Pharmacies
6.10.3. Drug Stores
6.10.4. Online Pharmacies
6.11. Drivers and Restraints: Impact Analysis
6.12. Market Attractiveness Analysis
6.12.1. By Country
6.12.2. By Drug Class
6.12.3. By Mode Of Administration
6.12.4. By Distribution Channel
6.13. Key Representative Market Participants
6.14. Key Participants Market Presence (Intensity Map)
7. Western Europe Vulvodynia Treatment Market Analysis 2013–2021 and Forecast 2022–2028
7.1. Introduction
7.2. Regional Market Dynamics
7.3. Historical Market Size (US$ Mn) By Country, 2013-2021
7.3.1. Germany
7.3.2. United Kingdom
7.3.3. France
7.3.4. Italy
7.3.5. Spain
7.3.6. Nordic Region
7.3.7. Rest of Western Europe
7.4. Market Size (US$ Mn) Forecast By Country, 2022-2028
7.4.1. Germany
7.4.2. United Kingdom
7.4.3. France
7.4.4. Italy
7.4.5. Spain
7.4.6. Nordic Region
7.4.7. Rest of Western Europe
7.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2021
7.5.1. Anticonvulsant
7.5.2. Tricyclic Antidepressant
7.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
7.5.4. Hormone
7.5.5. Nerve Block
7.5.6. Local Anesthetic
7.5.7. Others
7.6. Market Size (US$ Mn) Forecast and By Drug Class, 2022–2028
7.6.1. Anticonvulsant
7.6.2. Tricyclic Antidepressant
7.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
7.6.4. Hormone
7.6.5. Nerve Block
7.6.6. Local Anesthetic
7.6.7. Others
7.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2021
7.7.1. Oral
7.7.2. Topical
7.7.3. Injectable
7.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2022–2028
7.8.1. Oral
7.8.2. Topical
7.8.3. Injectable
7.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2021
7.9.1. Hospital Pharmacies
7.9.2. Retail Pharmacies
7.9.3. Drug Stores
7.9.4. Online Pharmacies
7.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2022–2028
7.10.1. Hospital Pharmacies
7.10.2. Retail Pharmacies
7.10.3. Drug Stores
7.10.4. Online Pharmacies
7.11. Drivers and Restraints: Impact Analysis
7.12. Market Attractiveness Analysis
7.12.1. By Country
7.12.2. By Drug Class
7.12.3. By Mode Of Administration
7.12.4. By Distribution Channel
7.13.Key Representative Market Participants
7.14.Key Participants Market Presence (Intensity Map)
8. Eastern Europe Vulvodynia Treatment Market Analysis 2013–2021 and Forecast 2022–2028
8.1. Introduction
8.2. Regional Market Dynamics
8.3. Historical Market Size (US$ Mn) By Country, 2013-2021
8.3.1. Russia
8.3.2. Poland
8.3.3. Rest of Eastern Europe
8.4. Market Size (US$ Mn) Forecast By Country, 2022-2028
8.4.1. Russia
8.4.2. Poland
8.4.3. Rest of Eastern Europe
8.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2021
8.5.1. Anticonvulsant
8.5.2. Tricyclic Antidepressant
8.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
8.5.4. Hormone
8.5.5. Nerve Block
8.5.6. Local Anesthetic
8.5.7. Others
8.6. Market Size (US$ Mn) Forecast and By Drug Class, 2022–2028
8.6.1. Anticonvulsant
8.6.2. Tricyclic Antidepressant
8.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
8.6.4. Hormone
8.6.5. Nerve Block
8.6.6. Local Anesthetic
8.6.7. Others
8.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2021
8.7.1. Oral
8.7.2. Topical
8.7.3. Injectable
8.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2022–2028
8.8.1. Oral
8.8.2. Topical
8.8.3. Injectable
8.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2021
8.9.1. Hospital Pharmacies
8.9.2. Retail Pharmacies
8.9.3. Drug Stores
8.9.4. Online Pharmacies
8.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2022–2028
8.10.1. Hospital Pharmacies
8.10.2. Retail Pharmacies
8.10.3. Drug Stores
8.10.4. Online Pharmacies
8.11. Drivers and Restraints: Impact Analysis
8.12. Market Attractiveness Analysis
8.12.1. By Country
8.12.2. By Drug Class
8.12.3. By Mode Of Administration
8.12.4. By Distribution Channel
8.13. Key Representative Market Participants
8.14. Key Participants Market Presence (Intensity Map)
9. Asia Pacific Excluding Japan Vulvodynia Treatment Market Analysis 2013–2021 and Forecast 2022–2028
9.1. Introduction
9.2. Regional Market Dynamics
9.3. Historical Market Size (US$ Mn) By Country, 2013-2021
9.3.1. China
9.3.2. India
9.3.3. Australia and New Zealand
9.3.4. ASEAN
9.3.5. Rest of APEJ
9.4. Market Size (US$ Mn) Forecast By Country, 2022-2028
9.4.1. China
9.4.2. India
9.4.3. Australia and New Zealand
9.4.4. ASEAN
9.4.5. Rest of APEJ
9.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2021
9.5.1. Anticonvulsant
9.5.2. Tricyclic Antidepressant
9.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
9.5.4. Hormone
9.5.5. Nerve Block
9.5.6. Local Anesthetic
9.5.7. Others
9.6. Market Size (US$ Mn) Forecast and By Drug Class, 2022–2028
9.6.1. Local Anesthetic
9.6.2. Anticonvulsant
9.6.3. Tricyclic Antidepressant
9.6.4. Hormones
9.6.5. Serotonin-norepinephrine reuptake inhibitors (SNRI)
9.6.6. Nerve Block
9.6.7. Others
9.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2021
9.7.1. Oral
9.7.2. Topical
9.7.3. Injectable
9.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2022–2028
9.8.1. Oral
9.8.2. Topical
9.8.3. Injectable
9.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2021
9.9.1. Hospital Pharmacies
9.9.2. Retail Pharmacies
9.9.3. Drug Stores
9.9.4. Online Pharmacies
9.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2022–2028
9.10.1. Hospital Pharmacies
9.10.2. Retail Pharmacies
9.10.3. Drug Stores
9.10.4. Online Pharmacies
9.11. Drivers and Restraints: Impact Analysis
9.12. Market Attractiveness Analysis
9.12.1. By Country
9.12.2. By Drug Class
9.12.3. By Mode Of Administration
9.12.4. By Distribution Channel
9.13. Key Representative Market Participants
9.14. Key Participants Market Presence (Intensity Map)
10. Japan Vulvodynia Treatment Market Analysis 2013–2021 and Forecast 2022–2028
10.1. Introduction
10.2. Regional Market Dynamics
10.3. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2021
10.3.1. Anticonvulsant
10.3.2. Tricyclic Antidepressant
10.3.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
10.3.4. Hormone
10.3.5. Nerve Block
10.3.6. Local Anesthetic
10.3.7. Others
10.4. Market Size (US$ Mn) Forecast and By Drug Class, 2022–2028
10.4.1. Anticonvulsant
10.4.2. Tricyclic Antidepressant
10.4.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
10.4.4. Hormone
10.4.5. Nerve Block
10.4.6. Local Anesthetic
10.4.7. Others
10.5. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2021
10.5.1. Oral
10.5.2. Topical
10.5.3. Injectable
10.6. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2022–2028
10.6.1. Oral
10.6.2. Topical
10.6.3. Injectable
10.7. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2021
10.7.1. Hospital Pharmacies
10.7.2. Retail Pharmacies
10.7.3. Drug Stores
10.7.4. Online Pharmacies
10.8. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2022–2028
10.8.1. Hospital Pharmacies
10.8.2. Retail Pharmacies
10.8.3. Drug Stores
10.8.4. Online Pharmacies
10.9. Drivers and Restraints: Impact Analysis
10.10. Market Attractiveness Analysis
10.10.1. By Drug Class
10.10.2. By Mode Of Administration
10.10.3. By Distribution Channel
10.11. Key Representative Market Participants
10.12. Key Participants Market Presence (Intensity Map)
11. Middle East and Africa Vulvodynia Treatment Market Analysis 2013–2021 and Forecast 2022–2028
11.1. Introduction
11.2. Regional Market Dynamics
11.2.1. Drivers
11.2.2. Restraints
11.2.3. Trends
11.3. Historical Market Size (US$ Mn) Analysis By Country, 2013–2021
11.3.1. GCC Countries
11.3.2. South Africa
11.3.3. Rest of MEA
11.4. Market Size (US$ Mn) Forecast By Country, , 2022–2028
11.4.1. GCC Countries
11.4.2. South Africa
11.4.3. Rest of MEA
11.5. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2021
11.5.1. Anticonvulsant
11.5.2. Tricyclic Antidepressant
11.5.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
11.5.4. Hormone
11.5.5. Nerve Block
11.5.6. Local Anesthetic
11.5.7. Others
11.6. Market Size (US$ Mn) Forecast and By Drug Class, 2022–2028
11.6.1. Anticonvulsant
11.6.2. Tricyclic Antidepressant
11.6.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
11.6.4. Hormone
11.6.5. Nerve Block
11.6.6. Local Anesthetic
11.6.7. Others
11.7. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2021
11.7.1. Oral
11.7.2. Topical
11.7.3. Injectable
11.8. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2022–2028
11.8.1. Oral
11.8.2. Topical
11.8.3. Injectable
11.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2021
11.9.1. Hospital Pharmacies
11.9.2. Retail Pharmacies
11.9.3. Drug Stores
11.9.4. Online Pharmacies
11.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2022–2028
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Drug Stores
11.10.4. Online Pharmacies
11.11. Drivers and Restraints: Impact Analysis
11.12. Market Attractiveness Analysis
11.12.1. By Country
11.12.2. By Drug Class
11.12.3. By Mode Of Administration
11.12.4. By Distribution Channel
11.13. Key Representative Market Participants
11.14. Key Participants Market Presence (Intensity Map)
12. Forecast Factors: Relevance and Impact
13. Forecast Assumptions
14. Competition Landscape
14.1. Competition Dashboard
14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
14.2.1. GlaxoSmithKline plc.
14.2.2. AstraZeneca Plc.
14.2.3. Eli Lilly and Company
14.2.4. Merck & Co., Inc.
14.2.5. Pfizer Inc.
14.2.6. Johnson & Johnson Services, Inc.
14.2.7. Allergan plc.
14.2.8. Depomed Inc.
14.2.9. Par pharmaceutical
14.2.10. Vertical pharmaceutical
15. Global Vulvodynia Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Region
15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Mn) Analysis By Region, 2013–2021
15.2.1. North America
15.2.2. Western Europe
15.2.3. Eastern Europe
15.2.4. Latin America
15.2.5. Asia Pacific Excluding Japan
15.2.6. Japan
15.2.7. Middle East and Africa
15.3. Market Size (US$ Mn) Forecast By Region, 2022–2028
15.3.1. North America
15.3.2. Western Europe
15.3.3. Eastern Europe
15.3.4. Latin America
15.3.5. Asia Pacific Excluding Japan
15.3.6. Japan
15.3.7. Middle East and Africa
15.4. Key Trends / Developments
15.5. Market Attractiveness Analysis By Region
16. Global Vulvodynia Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2013–2021
16.2.1. Anticonvulsant
16.2.2. Tricyclic Antidepressant
16.2.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
16.2.4. Hormone
16.2.5. Nerve Block
16.2.6. Local Anesthetic
16.2.7. Others
16.3. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028
16.3.1. Anticonvulsant
16.3.2. Tricyclic Antidepressant
16.3.3. Serotonin-norepinephrine reuptake inhibitors (SNRI)
16.3.4. Hormone
16.3.5. Nerve Block
16.3.6. Local Anesthetic
16.3.7. Others
16.4. Market Attractiveness Analysis By Drug Class
17. Global Vulvodynia Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Mode Of Administration
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Mode Of Administration, 2013–2021
17.2.1. Oral
17.2.2. Topical
17.2.3. Injectable
17.3. Market Size (US$ Mn) and Forecast, By Mode Of Administration, 2022–2028
17.3.1. Oral
17.3.2. Topical
17.3.3. Injectable
17.4. Market Attractiveness Analysis By Mode Of Administration
18. Global Vulvodynia Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013–2021
18.2.1. Hospital Pharmacies
18.2.2. Retail Pharmacies
18.2.3. Drug Stores
18.2.4. Online Pharmacies
18.3. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2022–2028
18.3.1. Hospital Pharmacies
18.3.2. Retail Pharmacies
18.3.3. Drug Stores
18.3.4. Online Pharmacies
18.4. Market Attractive Analysis By Distribution Channel
19. Global Vulvodynia Treatment Market Analysis 2013–2021 and Forecast 2022–2028
19.1. Market Size and Y-o-Y Growth
19.2. Absolute $ Opportunity
19.3. Value Chain
20. Assumptions and Acronyms Used
21. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: North America Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2021 and Forecast 2022-2028 By Country
Table 02: North America Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022-2028 By Drug Type
Table 03: North America Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2021 and Forecast 2022-2028, By mode of administration
Table 04: North America Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 05: Latin America Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Country
Table 06: Latin America Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Drug Type
Table 07: Latin America Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By mode of administration
Table 08: Latin America Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 09: Western Europe Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2021 and Forecast 2022–2028, By Country
Table 10: Western Europe Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Drug Type
Table 11: Western Europe Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2021 and Forecast 2022–2028, By mode of administration
Table 12: Western Europe Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 13: Eastern Europe Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2021 and Forecast 2022–2028, By Country
Table 14: Eastern Europe Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Drug Type
Table 15: Eastern Europe Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2021 and Forecast 2022–2028, By mode of administration
Table 16: Eastern Europe Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 17: Asia Pacific Excluding Japan Vulvodynia Treatment Market size (US$ Mn) Analysis, 2013–2021 and Forecast 2022–2028, By Country
Table 18: Asia Pacific Excluding Japan Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Drug Type
Table 19: Asia Pacific Excluding Japan Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2021 and Forecast 2022–2028, By mode of administration
Table 20: Asia Pacific Excluding Japan Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 21: Japan Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Drug Type
Table 22: Japan Vulvodynia Treatment Market size (US$ Mn)Analysis-22013–2021 and Forecast 2022–2028, By mode of administration
Table 23: Japan Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 24: Middle East and Africa Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Country
Table 25: Middle East and Africa Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Drug Type
Table 26: Middle East and Africa Vulvodynia Treatment Market size (US$ Mn)Analysis-2013–2021 and Forecast 2022–2028, By mode of administration
Table 27: Middle East and Africa Vulvodynia Treatment Market size (US$ Mn) Analysis-2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 28: Global Vulvodynia Treatment Market Size (US$ Mn) Forecast By Region, 2013-2022
Table 29: Global Vulvodynia Treatment Market Size Value (US$ Mn) Analysis 2012–2016 and Forecast 2022–2028 , By Drug Type
Table 30: Global Vulvodynia Treatment Market size (US$ Mn) Analysis 2022–2028 and Forecast 2021–2027, By Animal Type
Table 31: Global Vulvodynia Treatment Market size (US$ Mn) Analysis 2012–2016 and Forecast 2022–2028, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Pain Description by Vulvodynia Patient
Figure 02: Pain Location in Vulvodynia Patient
Figure 03: Additional Conditions Suffered By Vulvodynia Patient
Figure 04: Vulvodynia Treatment Market Split By Country (2021)
Figure 05: Vulvodynia Treatment Market Split By Drug Class (2021)
Figure 06: Vulvodynia Treatment Market Split By Mode of Administration (2021)
Figure 07: Vulvodynia Treatment Market Split By Distribution Channel (2021)
Figure 08: North America Vulvodynia Treatment Market Size Analysis, 2013–2021
Figure 09: North America Vulvodynia Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 10: U.S. Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2021
Figure 11: U.S. Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 12: Canada Vulvodynia Treatment, Market Size (US$ Mn) Analysis, 2013–2021
Figure 13: Canada Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 14: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 15: Anticonvulsant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 16: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 17: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 18: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 19: SNRIs Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 20: Hormone Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 21: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 22: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 23: Nerve Block Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 24: Local Anesthetic Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 25: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 26: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 27: Other Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 28: North America Vulvodynia Treatment Market Attractiveness Analysis By Country, 2022-2028
Figure 29: North America Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2022-2028
Figure 30: North America Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2022-2028
Figure 31: North America Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2022-2028
Figure 32: Vulvodynia Treatment Market Split By Country (2021)
Figure 33: Vulvodynia Treatment Market Split By Drug Class (2021)
Figure 34: Vulvodynia Treatment Market Split By Mode of Administration (2021)
Figure 35: Vulvodynia Treatment Market Split By Distribution Channel (2021)
Figure 36: Latin America Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 37: Latin America Vulvodynia Treatment Market Forecast & Y-o-Y growth, 2022-2028
Figure 38: Brazil Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 39: Brazil Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 40: Mexico Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 41: Mexico Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 42: Rest of Latin America Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 43: Rest of Latin America Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 44: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 45: Anticonvulsant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 46: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 47: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 48: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 49: SNRIs Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 50: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2013–2021
Figure 51: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 52: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 53: Nerve Block Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 54: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2013–2021
Figure 55: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 56: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 57: Other Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022-2028
Figure 58: Latin America Vulvodynia Treatment Market Attractiveness Analysis By Country, 2022-2028
Figure 59: Latin America Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2022-2028
Figure 60: Latin America Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2022-2028
Figure 61: Latin America Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2022-2028
Figure 62: Vulvodynia Treatment Market Split By Country (2021)
Figure 63: Vulvodynia Treatment Market Split By Drug Class (2021)
Figure 64: Vulvodynia Treatment Market Split By Mode of Administration (2021)
Figure 65: Vulvodynia Treatment Market Split By Distribution Channel (2021)
Figure 66: Western Europe Vulvodynia Treatment Market Size Analysis, 2013–2021
Figure 67: Western Europe Vulvodynia Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 68: U.K. Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2021
Figure 69: U.K. Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 70: Germany Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2021
Figure 71: Germany Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 72: France Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2021
Figure 73: France Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 74: Spain Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2021
Figure 75: Spain Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 76: Italy Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2021
Figure 77: Italy Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 78: Rest of Western Europe Vulvodynia Treatment , Market Size (US$ Mn) Analysis, 2013–2021
Figure 79: Rest of Western Europe Vulvodynia Treatment , Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 80: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 81: Anticonvulsant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 82: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 83: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 84: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 85: SNRIs Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 86: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2013–2021
Figure 87: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 88: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 89: Nerve Block Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 90: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2013–2021
Figure 91: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 92: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 93: Other Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 94: Western Europe Vulvodynia Treatment Market Attractiveness Analysis By Country, 2022–2028
Figure 95: Western Europe Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2022–2028
Figure 96: Western Europe Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2022–2028
Figure 97: Western Europe Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2022–2028
Figure 98: Vulvodynia Treatment Market Split By Country (2021)
Figure 99: Vulvodynia Treatment Market Split By Drug Class (2021)
Figure 100: Vulvodynia Treatment Market Split By Mode of Administration (2021)
Figure 101: Vulvodynia Treatment Market Split By Distribution Channel (2021)
Figure 102: Eastern Europe Vulvodynia Treatment Market Size Analysis, 2013–2021
Figure 103: Eastern Europe Vulvodynia Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 104: Russia Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 105: Russia Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 106: Poland Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 107: Poland Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 108: Rest of Eastern Europe Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 109: Rest of Eastern Europe Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 110: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 111: Anticonvulsant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 112: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 113: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 114: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 115: SNRIs Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 116: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 117: Hormone Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 118: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 119: Nerve Block Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 120: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 121: Local Anesthetic Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 122: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 123: Other Vulvodynia Treatment Market Forecast & Y-o-Y Growth (%), 2022–2028
Figure 124: Eastern Europe Vulvodynia Treatment Market Attractiveness Analysis By Country, 2022–2028
Figure 125: Eastern Europe Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2022–2028
Figure 126: Eastern Europe Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2022–2028
Figure 127: Eastern Europe Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2022–2028
Figure 128: Vulvodynia Treatment Market Split By Country (2021)
Figure 129: Vulvodynia Treatment Market Split By Drug Class (2021)
Figure 130: Vulvodynia Treatment Market Split By Mode of Administration (2021)
Figure 131: Vulvodynia Treatment Market Split By Distribution Channel (2021)
Figure 132: Asia Pacific Excluding Japan Vulvodynia Treatment Market Size Analysis (US$ Mn), 2013–2021
Figure 133: Asia Pacific Excluding Japan Vulvodynia Treatment Market Forecast (US$ Mn) (US$ Mn) & Y-o-Y growth (%), 2022–2028
Figure 134: China Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 135: China Vulvodynia Treatment Market Forecast (US$ Mn) (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 136: India Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 137: India Vulvodynia Treatment Market Forecast (US$ Mn) (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 138: Australia and New Zealand Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 139: Australia and New Zealand Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 140: Rest of APEJ Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 141: Rest of APEJ Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 142: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 143: Anticonvulsant Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 144: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 145: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 146: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 147: SNRIs Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 148: Hormone Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 149: Hormone Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 150: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 151: Nerve Block Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 152: Local Anesthetic Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 153: Local Anesthetic Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 154: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 155: Other Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 156: Asia Pacific Excluding Japan Vulvodynia Treatment Market Attractiveness Analysis By Country, 2022–2028
Figure 157: Asia Pacific Excluding Japan Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2022–2028
Figure 158: Asia Pacific Excluding Japan Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2022–2028
Figure 159: Asia Pacific Excluding Japan Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2022–2028
Figure 160: Vulvodynia Treatment Market Split By Drug Class (2021)
Figure 161: Vulvodynia Treatment Market Split By Mode of Administration (2021)
Figure 162: Vulvodynia Treatment Market Split By Distribution Channel (2021)
Figure 163: Japan Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 164: Japan Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y growth, 2022–2028
Figure 165: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 166: Anticonvulsant Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 167: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2012–2016
Figure 168: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 169: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 170: SNRIs Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 171: Hormone Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 172: Hormone Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 173: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 174: Nerve Block Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 175: Local Anesthetic Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 176: Local Anesthetic Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 177: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 178: Other Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 179: Japan Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2022–2028
Figure 180: Japan Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2022–2028
Figure 181: Japan Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2022–2028
Figure 182: Vulvodynia Treatment Market Split By Country (2021)
Figure 183: Vulvodynia Treatment Market Split By Drug Class (2021)
Figure 184: Vulvodynia Treatment Market Split By Mode of Administration (2021)
Figure 185: Vulvodynia Treatment Market Split By Distribution Channel (2021)
Figure 186: Middle East and Africa Vulvodynia Treatment Market Size Analysis, 2013–2021
Figure 187: Middle East and Africa Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y growth, 2022–2028
Figure 188: GCC Countries Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 189: GCC Countries Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 190: South Africa Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2012–2016
Figure 191: South Africa Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 192: Rest of MEA Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 193: Rest of MEA Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 194: Anticonvulsant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 195: Anticonvulsant Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 196: Tricyclic Antidepressant Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 197: Tricyclic Antidepressant Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 198: SNRIs Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 199: SNRIs Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 200: Hormone Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 201: Hormone Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 202: Nerve Block Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 203: Nerve Block Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 204: Local Anesthetic Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 205: Local Anesthetic Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 206: Other Vulvodynia Treatment Market Size (US$ Mn) Analysis, 2013–2021
Figure 207: Other Vulvodynia Treatment Market Forecast (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 208: Middle East and Africa Vulvodynia Treatment Market Attractiveness Analysis By Country, 2022–2028
Figure 209: Middle East and Africa Vulvodynia Treatment Market Attractiveness Analysis By Drug Class, 2022–2028
Figure 210: Middle East and Africa Vulvodynia Treatment Market Attractiveness Analysis By Mode of Administration, 2022–2028
Figure 211: Middle East and Africa Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2022–2028
Figure 212: Global Vulvodynia Treatment Market Attractiveness Analysis By Region, 2022–2028
Figure 213: Global Vulvodynia Treatment Market Attractiveness Analysis By Drug Type, 2022–2028
Figure 214: Global Vulvodynia Treatment Market Attractiveness Analysis By Animal Type, 2022–2028
Figure 215: Global Vulvodynia Treatment Market Attractiveness Analysis By Distribution Channel, 2022–2028
Figure 216: Global Vulvodynia Treatment Market Value Analysis and Forecast, 2021–2028 (US$ Mn
Figure 217: Global Vulvodynia Treatment Market Absolute $ Opportunity (US$ Mn), 2021–2028
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
